Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil Oral Suspension USP, 200 mg/mL. This is a generic equivalent used as an immunosuppressant, commonly prescribed to organ transplant patients to prevent organ rejection. The approval allows the company to manufacture and market this generic formulation in the US market. Mycophenolate Mofetil is a well-established molecule with steady demand in the transplant and autoimmune therapy segments.
Positive for the company — adds another product to its US generics portfolio, potentially opening up a new revenue stream from the US market, though it will face competition from other generic manufacturers.